Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2001 1
2002 2
2003 1
2004 1
2005 4
2006 6
2007 2
2009 4
2011 2
2017 2
2019 2
2021 1
2022 4
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

32 results

Results by year

Filters applied: . Clear all
Page 1
Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: interim analysis of the GMMG-CONCEPT trial.
Leypoldt LB, Besemer B, Asemissen AM, Hänel M, Blau IW, Görner M, Ko YD, Reinhardt HC, Staib P, Mann C, Lutz R, Munder M, Graeven U, Peceny R, Salwender H, Jauch A, Zago M, Benner A, Tichy D, Bokemeyer C, Goldschmidt H, Weisel KC. Leypoldt LB, et al. Among authors: asemissen am. Leukemia. 2022 Mar;36(3):885-888. doi: 10.1038/s41375-021-01431-x. Epub 2021 Nov 3. Leukemia. 2022. PMID: 34732857 Free PMC article. Clinical Trial. No abstract available.
Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial.
Goldschmidt H, Mai EK, Bertsch U, Fenk R, Nievergall E, Tichy D, Besemer B, Dürig J, Schroers R, von Metzler I, Hänel M, Mann C, Asemissen AM, Heilmeier B, Weinhold N, Huhn S, Kriegsmann K, Luntz SP, Holderried TAW, Trautmann-Grill K, Gezer D, Klaiber-Hakimi M, Müller M, Khandanpour C, Knauf W, Scheid C, Munder M, Geer T, Riesenberg H, Thomalla J, Hoffmann M, Raab MS, Salwender HJ, Weisel KC; German-Speaking Myeloma Multicenter Group (GMMG) HD7 investigators. Goldschmidt H, et al. Among authors: asemissen am. Lancet Haematol. 2022 Nov;9(11):e810-e821. doi: 10.1016/S2352-3026(22)00263-0. Lancet Haematol. 2022. PMID: 36328040 Clinical Trial.
Leishmania infantum reactivation with secondary IgA nephropathy.
Grewe I, Brehm TT, Kreuels B, Steinmetz OM, Dumoulin B, Asemissen AM, Tappe D, Ramharter M, Schmiedel S. Grewe I, et al. Among authors: asemissen am. J Travel Med. 2022 Nov 4;29(7):taac038. doi: 10.1093/jtm/taac038. J Travel Med. 2022. PMID: 35285886 No abstract available.
Surgical Site Cytology to Diagnose Spinal Lesions.
Koepke LG, Heuer A, Stangenberg M, Dreimann M, Welker L, Bokemeyer C, Strahl A, Asemissen AM, Viezens L. Koepke LG, et al. Among authors: asemissen am. Diagnostics (Basel). 2022 Jan 26;12(2):310. doi: 10.3390/diagnostics12020310. Diagnostics (Basel). 2022. PMID: 35204401 Free PMC article.
Rational peptide-based tumour vaccine development and T cell monitoring.
Scheibenbogen C, Letsch A, Schmittel A, Asemissen AM, Thiel E, Keilholz U. Scheibenbogen C, et al. Among authors: asemissen am. Semin Cancer Biol. 2003 Dec;13(6):423-9. doi: 10.1016/j.semcancer.2003.09.006. Semin Cancer Biol. 2003. PMID: 15001161 Review.
Comparison of bone marrow and peripheral blood aberrant plasma cell assessment by NGF in patients with MM.
Kriegsmann K, Manta C, Schwab R, Mai EK, Raab MS, Salwender HJ, Fenk R, Besemer B, Dürig J, Schroers R, von Metzler I, Hänel M, Mann C, Asemissen AM, Heilmeier B, Bertsch U, Huhn S, Müller-Tidow C, Goldschmidt H, Hundemer M. Kriegsmann K, et al. Among authors: asemissen am. Blood Adv. 2023 Feb 14;7(3):379-383. doi: 10.1182/bloodadvances.2022008005. Blood Adv. 2023. PMID: 35914229 Free PMC article. No abstract available.
Vaccination strategies in patients with renal cell carcinoma.
Asemissen AM, Brossart P. Asemissen AM, et al. Cancer Immunol Immunother. 2009 Jul;58(7):1169-74. doi: 10.1007/s00262-009-0706-7. Epub 2009 Apr 10. Cancer Immunol Immunother. 2009. PMID: 19360405 Free PMC article.
If it ain't broke, don't fix it!
Asemissen AM, Giagounidis A. Asemissen AM, et al. Haematologica. 2011 Nov;96(11):e44. doi: 10.3324/haematol.2011.050872. Haematologica. 2011. PMID: 22058282 Free PMC article. No abstract available.
CMV-specific central memory T cells reside in bone marrow.
Letsch A, Knoedler M, Na IK, Kern F, Asemissen AM, Keilholz U, Loesch M, Thiel E, Volk HD, Scheibenbogen C. Letsch A, et al. Among authors: asemissen am. Eur J Immunol. 2007 Nov;37(11):3063-8. doi: 10.1002/eji.200636930. Eur J Immunol. 2007. PMID: 17960663 Free article.
Functional CCR9 expression is associated with small intestinal metastasis.
Letsch A, Keilholz U, Schadendorf D, Assfalg G, Asemissen AM, Thiel E, Scheibenbogen C. Letsch A, et al. Among authors: asemissen am. J Invest Dermatol. 2004 Mar;122(3):685-90. doi: 10.1111/j.0022-202X.2004.22315.x. J Invest Dermatol. 2004. PMID: 15086554 Free article.
32 results